Noncholinergic treatment options for Alzheimer's disease.
Approved treatments for Alzheimer's disease have focused primarily on cholinergic enhancement. New attention, however, is being turned toward preventative treatments such as vitamin E, estrogen, and lipid-lowering agents. Preventative treatments focus on intervening prior to the onset of disease. These treatments are designed to modify the amyloid load. These new approaches require designs that select nonimpaired or minimally impaired populations, using new outcomes with prolonged assessment. The cost of these studies is high, but the potential benefit of delay or prevention of disease is the valuable goal.
Sano
Mary
M
Bronx Veterans Medical Research Development, Bronx, NY 10468-3904, USA. mary.sano@mssm.edu
D000368:Aged; D000544:Alzheimer Disease / Q000188:drug therapy* / Q000517:prevention & control* / Q000523:psychology; D000818:Animals; D000924:Anticholesteremic Agents / Q000627:therapeutic use; D000975:Antioxidants / Q000627:therapeutic use; D001526:Behavioral Symptoms / Q000188:drug therapy / Q000517:prevention & control / Q000523:psychology; D002986:Clinical Trials as Topic / Q000379:methods; D003072:Cognition Disorders / Q000188:drug therapy / Q000517:prevention & control / Q000523:psychology; D004967:Estrogens / Q000627:therapeutic use; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D000960:Hypolipidemic Agents / Q000627:therapeutic use; D008875:Middle Aged; D018579:Patient Selection; D012107:Research Design / Q000592:standards; D012642:Selegiline / Q000627:therapeutic use; D014810:Vitamin E / Q000627:therapeutic use
D000924:Anticholesteremic Agents; D000975:Antioxidants; D004967:Estrogens; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D000960:Hypolipidemic Agents; D014810:Vitamin E; D012642:Selegiline